Actinogen Medical   Report issue

For profit Phase 2
Founded: Sydney Australia (2014)

Organization Overview

First Clinical Trial
2015
NCT02616445
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Actinogen Medical | Actinogen Medical Limited

Active Ingredients

Drugs in Phase 2 Trials (2)

ue2343 (2 trials)

xanamem (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 2)

Dementia (Phase 2)

Peripheral Nervous System Diseases (Phase 1)

Small Fiber Neuropathy (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 2